WO1998029550A1 - Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico - Google Patents
Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico Download PDFInfo
- Publication number
- WO1998029550A1 WO1998029550A1 PCT/ES1997/000313 ES9700313W WO9829550A1 WO 1998029550 A1 WO1998029550 A1 WO 1998029550A1 ES 9700313 W ES9700313 W ES 9700313W WO 9829550 A1 WO9829550 A1 WO 9829550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prrsv
- protein
- gly
- leu
- wing
- Prior art date
Links
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 title claims abstract description 97
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 59
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 59
- 238000003745 diagnosis Methods 0.000 title claims description 19
- 230000004927 fusion Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 150000001413 amino acids Chemical class 0.000 claims abstract description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 4
- 101710202200 Endolysin A Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 18
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 239000003999 initiator Substances 0.000 description 9
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000004690 coupled electron pair approximation Methods 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 5
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 108010078144 glutaminyl-glycine Proteins 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 4
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 4
- 238000011537 Coomassie blue staining Methods 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000701867 Enterobacteria phage T7 Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- MMGCRPZQZWTZTA-IHRRRGAJSA-N Arg-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N MMGCRPZQZWTZTA-IHRRRGAJSA-N 0.000 description 3
- VJTWLBMESLDOMK-WDSKDSINSA-N Asn-Gln-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VJTWLBMESLDOMK-WDSKDSINSA-N 0.000 description 3
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MRNRMSDVVSKPGM-AVGNSLFASA-N Phe-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRNRMSDVVSKPGM-AVGNSLFASA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 2
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 2
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 2
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 2
- KBBKCNHWCDJPGN-GUBZILKMSA-N Arg-Gln-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KBBKCNHWCDJPGN-GUBZILKMSA-N 0.000 description 2
- GFMWTFHOZGLTLC-AVGNSLFASA-N Arg-His-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(O)=O GFMWTFHOZGLTLC-AVGNSLFASA-N 0.000 description 2
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 2
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 2
- LYJXHXGPWDTLKW-HJGDQZAQSA-N Arg-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O LYJXHXGPWDTLKW-HJGDQZAQSA-N 0.000 description 2
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 2
- WPOLSNAQGVHROR-GUBZILKMSA-N Asn-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N WPOLSNAQGVHROR-GUBZILKMSA-N 0.000 description 2
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 2
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 2
- SYZWMVSXBZCOBZ-QXEWZRGKSA-N Asn-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N SYZWMVSXBZCOBZ-QXEWZRGKSA-N 0.000 description 2
- CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 2
- PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 2
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 2
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 2
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 2
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- BIVLWXQGXJLGKG-BIIVOSGPSA-N Cys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N)C(=O)O BIVLWXQGXJLGKG-BIIVOSGPSA-N 0.000 description 2
- SAEVTQWAYDPXMU-KATARQTJSA-N Cys-Thr-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O SAEVTQWAYDPXMU-KATARQTJSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- ODBLJLZVLAWVMS-GUBZILKMSA-N Gln-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N ODBLJLZVLAWVMS-GUBZILKMSA-N 0.000 description 2
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 2
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 2
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 2
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 2
- FMBWLLMUPXTXFC-SDDRHHMPSA-N Glu-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N)C(=O)O FMBWLLMUPXTXFC-SDDRHHMPSA-N 0.000 description 2
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 2
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- XLFHCWHXKSFVIB-BQBZGAKWSA-N Gly-Gln-Gln Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLFHCWHXKSFVIB-BQBZGAKWSA-N 0.000 description 2
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 2
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 2
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 2
- WZSHYFGOLPXPLL-RYUDHWBXSA-N Gly-Phe-Glu Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O WZSHYFGOLPXPLL-RYUDHWBXSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ULRFSEJGSHYLQI-YESZJQIVSA-N His-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O ULRFSEJGSHYLQI-YESZJQIVSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 description 2
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 2
- GNRPTBRHRRZCMA-RWMBFGLXSA-N Leu-Met-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N GNRPTBRHRRZCMA-RWMBFGLXSA-N 0.000 description 2
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 2
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 2
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 2
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 2
- HQXSFFSLXFHWOX-IXOXFDKPSA-N Lys-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N)O HQXSFFSLXFHWOX-IXOXFDKPSA-N 0.000 description 2
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 2
- PELXPRPDQRFBGQ-KKUMJFAQSA-N Lys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O PELXPRPDQRFBGQ-KKUMJFAQSA-N 0.000 description 2
- BQVJARUIXRXDKN-DCAQKATOSA-N Met-Asn-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BQVJARUIXRXDKN-DCAQKATOSA-N 0.000 description 2
- SXWQMBGNFXAGAT-FJXKBIBVSA-N Met-Gly-Thr Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SXWQMBGNFXAGAT-FJXKBIBVSA-N 0.000 description 2
- CIIJWIAORKTXAH-FJXKBIBVSA-N Met-Thr-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O CIIJWIAORKTXAH-FJXKBIBVSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 2
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 2
- 108010003201 RGH 0205 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 2
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 description 2
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 2
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 2
- QZOSVNLXLSNHQK-UWVGGRQHSA-N Tyr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QZOSVNLXLSNHQK-UWVGGRQHSA-N 0.000 description 2
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 2
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 2
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 2
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 2
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 2
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 2
- VSCIANXXVZOYOC-AVGNSLFASA-N Val-Pro-His Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N VSCIANXXVZOYOC-AVGNSLFASA-N 0.000 description 2
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 2
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 101150106875 malE gene Proteins 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-MBOVONDJSA-N (2r,3r,4s,5r)-2-(hydroxymethyl)-6-propan-2-ylsulfanyloxane-3,4,5-triol Chemical compound CC(C)SC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-MBOVONDJSA-N 0.000 description 1
- -1 2,2'-azino-di [ethyl] Chemical class 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- OXXJZDJLYSMGIQ-ZRDIBKRKSA-N 8-[2-[(e)-3-hydroxypent-1-enyl]-5-oxocyclopent-3-en-1-yl]octanoic acid Chemical compound CCC(O)\C=C\C1C=CC(=O)C1CCCCCCCC(O)=O OXXJZDJLYSMGIQ-ZRDIBKRKSA-N 0.000 description 1
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 1
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 1
- JPGBXANAQYHTLA-DRZSPHRISA-N Ala-Gln-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JPGBXANAQYHTLA-DRZSPHRISA-N 0.000 description 1
- NJWJSLCQEDMGNC-MBLNEYKQSA-N Ala-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N)O NJWJSLCQEDMGNC-MBLNEYKQSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
- 101100397117 Arabidopsis thaliana PPA3 gene Proteins 0.000 description 1
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 1
- VKCOHFFSTKCXEQ-OLHMAJIHSA-N Asn-Asn-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VKCOHFFSTKCXEQ-OLHMAJIHSA-N 0.000 description 1
- KUYKVGODHGHFDI-ACZMJKKPSA-N Asn-Gln-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O KUYKVGODHGHFDI-ACZMJKKPSA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 1
- YZKOXEJTLWZOQL-GUBZILKMSA-N Cys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N YZKOXEJTLWZOQL-GUBZILKMSA-N 0.000 description 1
- LMXOUGMSGHFLRX-CIUDSAMLSA-N Cys-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N LMXOUGMSGHFLRX-CIUDSAMLSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 1
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 1
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 1
- OZEQPCDLCDRCGY-SOUVJXGZSA-N Gln-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)N)C(=O)O OZEQPCDLCDRCGY-SOUVJXGZSA-N 0.000 description 1
- XUMFMAVDHQDATI-DCAQKATOSA-N Gln-Pro-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUMFMAVDHQDATI-DCAQKATOSA-N 0.000 description 1
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 1
- LGWNISYVKDNJRP-FXQIFTODSA-N Gln-Ser-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGWNISYVKDNJRP-FXQIFTODSA-N 0.000 description 1
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
- WOSRKEJQESVHGA-CIUDSAMLSA-N Glu-Arg-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O WOSRKEJQESVHGA-CIUDSAMLSA-N 0.000 description 1
- CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
- BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 description 1
- LXTRSHQLGYINON-DTWKUNHWSA-N Gly-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN LXTRSHQLGYINON-DTWKUNHWSA-N 0.000 description 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
- OZBDSFBWIDPVDA-BZSNNMDCSA-N His-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N OZBDSFBWIDPVDA-BZSNNMDCSA-N 0.000 description 1
- CNHSMSFYVARZLI-YJRXYDGGSA-N His-His-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CNHSMSFYVARZLI-YJRXYDGGSA-N 0.000 description 1
- 101001057699 Homo sapiens Inorganic pyrophosphatase Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
- 102100027050 Inorganic pyrophosphatase Human genes 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- MSSABBQOBUZFKZ-IHRRRGAJSA-N Lys-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O MSSABBQOBUZFKZ-IHRRRGAJSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 1
- WWWGMQHQSAUXBU-BQBZGAKWSA-N Met-Gly-Asn Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O WWWGMQHQSAUXBU-BQBZGAKWSA-N 0.000 description 1
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 1
- MPCKIRSXNKACRF-GUBZILKMSA-N Met-Pro-Asn Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O MPCKIRSXNKACRF-GUBZILKMSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 1
- WIPAMEKBSHNFQE-IUCAKERBSA-N Pro-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1 WIPAMEKBSHNFQE-IUCAKERBSA-N 0.000 description 1
- ZAUHSLVPDLNTRZ-QXEWZRGKSA-N Pro-Val-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZAUHSLVPDLNTRZ-QXEWZRGKSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- PVDTYLHUWAEYGY-CIUDSAMLSA-N Ser-Glu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PVDTYLHUWAEYGY-CIUDSAMLSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- KEGBFULVYKYJRD-LFSVMHDDSA-N Thr-Ala-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KEGBFULVYKYJRD-LFSVMHDDSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- FHDLKMFZKRUQCE-HJGDQZAQSA-N Thr-Glu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHDLKMFZKRUQCE-HJGDQZAQSA-N 0.000 description 1
- XSTGOZBBXFKGHA-YJRXYDGGSA-N Thr-His-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O XSTGOZBBXFKGHA-YJRXYDGGSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- REJBPZVUHYNMEN-LSJOCFKGSA-N Val-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N REJBPZVUHYNMEN-LSJOCFKGSA-N 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- GXAZTLJYINLMJL-LAEOZQHASA-N Val-Asn-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GXAZTLJYINLMJL-LAEOZQHASA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
- G01N2333/17—Porcine transmissible gastroenteritis virus
Definitions
- This invention relates, in general, to recombinant proteins suitable for the diagnosis of a porcine pathogen, in particular, to recombinant fusion proteins comprising the porcine reproductive and respiratory syndrome virus (PRRSV) nucleocapsid protein obtained from both isolates.
- PRRSV porcine reproductive and respiratory syndrome virus
- PRRS porcine reproductive and respiratory syndrome
- PRRSV causes an important pathology in the pig hut characterized by reproductive disorders in sows (abortions, birth of dead or weak piglets), and an increase in perinatal mortality as well as dyspnea and pneumonia in piglets [Terpstra et al., Vet. Quarterly, 13, (1991), 131-136].
- PRRSV is a covered RNA virus, approximately 62 nm in diameter, whose viral genome comprises a single-stranded RNA and positive polarity about 15 ilobases (kb) in length.
- the genome contains 8 overlapping open reading (ORF) phases [Meulenberg et al., Virology, 192, (1993), 62-72].
- the virion contains 6 structural proteins encoded by ORFs 2 to 7 [Meulenberg et al., Virology, 206, (1995), 155-163; van Nieuwstadt et al., J. Virol., 70, (1996), 4767-4772].
- the 0RF7 encodes the nucleocapsid protein (N protein) that is the most immunogenic protein of PRRSV [Sanz et al., Second Symposium on Aujeszky and PRRS viruses, Copenhagen, Denmark (1995)], making it a good candidate for detection of virus-specific antibodies, and, consequently, for the diagnosis of the disease.
- PRRSV isolates Two different antigenic groups of PRRSV have been described, corresponding to the American and European isolates.
- Japanese PRRSV isolates, as well as other Asian isolates are antigenically related to the American isolate.
- a characteristic example of the European PRRSV isolate is that deposited in the ECACC with the deposit number V93070108 [Spanish patent ES 2,074,950], while a representative example of the American PRRSV isolate is the one identified as VR-2332 [European EP patent 0 529 584].
- European and American PRRSV isolates have a different genotype [Meng et al., Archives of Virology, 140 (1995), 745-755] with significant antigenic differences [ensvoort et al., J. Vet. Diag. Inves., 4, (1992), 134-138].
- kits to detect the presence of PRRSV or antibodies that recognize PRRSV specific to the European and American isolated There are kits to detect the presence of PRRSV or antibodies that recognize PRRSV specific to the European and American isolated.
- the usual methods of diagnosing PRRSV include performing an immuno-peroxidase-based assay (IPMA) or conducting an ELISA-type assay based on alveolar macrophages of pig lung or on antigenic recombinant proteins.
- IPMA immuno-peroxidase-based assay
- ELISA-type assay based on alveolar macrophages of pig lung or on antigenic recombinant proteins.
- IPMA-based techniques are expensive and bloody techniques, requiring the use of alveolar pig lung macrophages from animal slaughter, such macrophages being contaminated or infected with other pathogens (unless gnotobiotic or specific pathogen-free animals are sacrificed , SPF), and are not susceptible to automation as they require a visual inspection by microscope.
- ELISA techniques based on macrophages require the use of macrophage extracts, so they present the same problems, in that sense, as IPMA-based techniques.
- the use of antigen in the form of a cell extract requires an internal reference with the same cell extracts but without infecting, in case there is any serum from a field animal with natural reactivity, that is, it has natural antibodies, which could mask the Outcome.
- PRRSV antigens for example the nucleocapsid protein
- tissue culture is problematic and expensive.
- PRRSV recombinant proteins using recombinant baculovirus in permissive cells poses numerous problems since the expression of said proteins in that system is expensive and inefficient, the expressed proteins are insoluble and only a small soluble fraction is recovered. which is the one used in the ELISA.
- the products of PRRSV ORF 3, 5 and 7 expressed by recombinant baculovirus in insect cells are difficult to purify.
- an uninfected insect cell reference should be included to rule out natural reactivity.
- diagnostic methods should be reliable, reproducible, sensitive, simple, cheap, broad spectrum and, advantageously, should use active antigens whose production in unlimited quantities is simple and economical. Additionally, in the case of pathogens that have isolates with genetic, antigenic and pathogenic differences, it is convenient to discriminate between the different isolates.
- the invention provides recombinant fusion proteins, which comprise the PRRSV nucleocapsid protein obtained from both European and American isolates, useful for the diagnosis of PRRSV.
- the invention also provides methods and kits for the diagnosis of PRRSV comprising the use of said recombinant fusion proteins.
- the nucleic acid sequences that essentially encode said recombinant fusion proteins constitute a further object of the present invention.
- the recombinant fusion proteins object of this invention comprise an amino acid sequence selected from the identified sequences (see section on the LIST OF SEQUENCES) as SEC. ID. N .: 1 and SEC. ID. No. : 2, or an active fragment thereof.
- active fragment in the sense used in this description, refers to a protein fragment properly recognized by positive sera against PRRSV, that is, a fragment of the PRRSV ORF7 recognized in such a way as to allow discrimination between sera. PRRSV positive and negative.
- SEC. ID. No. : 1 shows the amino acid sequence corresponding to the nucleocapsid protein of a European PRRSV isolate, specifically that identified as Toledo 4/96 [Example 1], generally referred to as "European isolate” in this description
- SEC. ID. No. : 2 shows the amino acid sequence corresponding to the nucleocapsid protein of an American isolate, specifically that identified as Canada 14/96 [Example 2], generally referred to as "American isolate” in this description.
- Recombinant fusion proteins further comprise an amino acid sequence, of variable length and composition, derived from the system chosen for the expression of the recombinant fusion protein, to which the SEC is fused. ID. N .: 1, or SEC. ID. No. : 2, or an active fragment thereof, either directly or through a junction zone formed by a small number of amino acids derived from the genetic manipulation of the recombinant fusion protein expression system.
- amino acid sequences include all or part of the product of gene 10 of phage T7, glutathione-S-transferase, ⁇ -galactosidase and the product of the malE gene.
- recombinant fusion proteins consist of an amino acid sequence selected from the SEC. ID. No. : 1 and SEC. ID. No. : 2, or an active fragment thereof, fused to a remainder of 259 amino acids from the T10 phage gene 10 protein through a 4-6 amino acid binding zone.
- recombinant fusion proteins have the amino acid sequences identified as SEC. ID. No. : 8 or SEC. ID. No. : 9.
- Recombinant fusion proteins provided by this invention can be obtained by expression of the sequence encoding the PRRSV nucleocapsid protein fused to the sequence encoding another protein or a separate one from it as occurs, for example, with plasmids pET, pGEX , pEx and pMal, which contain the 10 phage T7 gene, the glutathione-S-transferase gene, the ⁇ -galactosidase gene and the malE gene respectively, in a suitable expression system, such as a prokaryotic, by example a microorganism belonging to the genus
- Escherichia Bacillus, Salmonella, Listeria, Yersinia, etc.
- the sequence encoding the PRRSV nucleocapsid protein can be obtained from the viral RNA by conventional methods comprising, for example, the synthesis of a copy DNA (cDNA) by reverse transcription and the enzymatic amplification of the nucleic acid fragment it contains.
- the PRRSV ORF 7 gene through the polymerase chain reaction (PCR) using the appropriate primers.
- the complete sequence encoding the PRRSV nucleocapsid protein is cloned into a plasmid that is used to transform appropriate host cells.
- the plasmid with the complete sequence of the PRRSV ORF7 is stabilized by cloning in a suitable cellular system, where the orientation and size of the insert is also checked, and subsequently cloned into the appropriate host cells for expression of the recombinant fusion protein. Any of the commonly used plasmids can be used in the transformation of prokaryotes.
- the correct expression of the recombinant proteins was analyzed by polyacrylamide gel and sodium dodecyl sulfate (SDS-PAGE) electrophoresis and Coomassie blue staining or by immunoblotting, while its antigenicity was determined by an ELISA assay.
- the complete sequence of the PRRSV ORF7 both from the European isolate and the American isolate, has been cloned into plasmid pET3x, has been stabilized in E cells.
- coli DH5 where, after checking the orientation and size, it has been extracted and cloned into E cells.
- coli BL21 for the expression of the corresponding recombinant fusion protein.
- the recombinant fusion proteins of this invention containing the nucleocapsid protein of either the European isolate or the American PRRSV isolate, have been expressed in E. coli BL21 with very high expression levels when expressed as large fusion proteins [45 or 46 kilodaltons (KDa)] (see Examples 3.4.1 and 4.4.1).
- KDa 46 kilodaltons
- Previous attempts to express the PRRSV nucleocapsid protein without fusing to other proteins or fragments thereof, or as small fusion proteins did not allow producing detectable levels of said protein.
- the recombinant fusion proteins provided by this invention produce inclusion bodies, such proteins can be easily recovered by solubilization with guanidinium chloride.
- the recombinant proteins of this invention without any further manipulation, except a simple dilution in phosphate buffered saline (PBS), can be used to coat a suitable solid support prior to use for diagnostic purposes.
- PBS phosphate buffered s
- PRRSV nucleocapsid protein as a recombinant fusion protein in E. coli takes place at very high levels and can be purified. easily so that this protein is an ideal candidate for the development of methods and kits for the diagnosis of PRRSV.
- the recombinant fusion proteins provided by this invention are useful as a diagnostic reagent. This hypothesis is confirmed by the fact that monoclonal antibodies that compete efficiently with PRRSV-positive sera, recognize only the complete protein (Examples 3.4.2 and 4.4.2). In addition, the most immunodominant epitope, the one recognized by monoclonal antibodies 1CH5 and 1DH10, is a conformation-dependent epitope that requires the complete sequence of the nucleocapsid protein to be recognized.
- the invention also provides a method for the diagnosis of PRRSV, in particular, a method for detecting the presence of antibodies that specifically recognize PRRSV, which comprises contacting a biological sample of an animal with a recombinant fusion protein provided by this invention. under conditions that allow the formation of an antigen-antibody complex, and detect the antigen-antibody complex formed.
- biological sample refers to a sample from an animal, such as blood, serum, plasma, sputum, saliva or any other biological fluid, while the term “animal” includes all mammals, more specifically pigs, sows and piglets.
- the immunoassay can be, for example, an indirect ELISA or a competition ELISA.
- the detection of the antigen-antibody complex can be carried out by conventional techniques that include the production of a colored reaction, using, for example, a reagent labeled an enzyme, such as peroxidase, and a suitable substrate.
- the invention provides a kit for the diagnosis of PRRSV, in particular, a kit for detecting the presence of antibodies that specifically recognize PRRSV in a biological sample of an animal, which includes a recombinant fusion protein provided by this invention and suitable means of detecting the antigen complex. antibody formed comprising the labeled reagent and the appropriate substrate.
- the diagnostic kit may also contain a positive control and a negative control in order to facilitate the evaluation of the test results by comparison with the results obtained with the standard sample.
- the ORF7 of said isolate was obtained by means of a reverse transcription reaction (TR) followed by enzymatic amplification by the polymerase chain reaction (PCR) of the serum of the infected animal.
- TR reverse transcription reaction
- PCR polymerase chain reaction
- 100 ⁇ l of serum is added 600 ⁇ l of Chaos buffer [to prepare 100 ml of Chaos buffer 50 g of guanidinium thiocyanate (GSCN) 4.2 M, 2.5 ml of 20% sarcosyl are mixed, 1.25 ml of Tris-HCl, pH: 8.2 M, 99.7 ml of water, filtered through a 0.22 ⁇ filter and 0.7 mol of ⁇ -mercaptoethanol] are added and incubated the whole for 30 minutes at room temperature.
- GSCN guanidinium thiocyanate
- RNA is precipitated with 1/10 (volume) of 3M sodium acetate pH: 5.2 and 3 volumes of absolute ethanol, washed with 70% ethanol and the precipitate is dried. RNA is resuspended in 20 ⁇ l of T: E buffer [Tris: EDTA, 10: 1 mM, pH: 7.5].
- RNA suspension formed 10 ⁇ l of the suspension formed is used.
- 500 ng of the complementary initiator oligonucleotide, identified as SEC is added to 10 ⁇ l of said RNA suspension.
- ID. N .: 4 incubating the set for 10 minutes at 65 ° C. The mixture is allowed to cool slowly to room temperature.
- dNTPs deoxynucleoside triphosphates
- the amplification products were detected by electrophoresis in a 1% agarose gel stained with ethidium bromide and observed by ultraviolet light ( ⁇ : 300 nm) in a Fotodyne transilluminator.
- the ORF7 of said isolate was obtained by means of a TR-PCR reaction according to the procedure described in Example 1, but using as oligonucleotide initiator for reverse transcription the one identified as SEC. ID.
- ORF7 of the European isolate was cloned into plasmid pMTL25 previously digested with Smal and treated with phosphatase, in order to provide BamHI sites compatible with expression vectors.
- the resulting plasmid was named pPRRSE-ORF7.
- Plasmid DNA was sequenced according to the method of the dideoxynucleotides [Sanger et al., Proc. Nati Acad. Sci. USA, 74, (1977), 5463-5467].
- the putative amino acid sequence derived from said nucleotide sequence, corresponding to the nucleocapsid protein of the European PRRSV isolate is shown in SEC. ID. No .: 1.
- the protein sequence analysis was performed with the PC / GENE program and PredictProtein [Rost et al., Meth. Enzymol., 266, (1996), 525-539].
- Plasmid pET3x containing the complete sequence of the PRRSV nucleocapsid protein was called pET-PRRSVORF7E and was used to transform E cells.
- coli XLl blue or DH5 competent in order to stabilize the plasmid and check the orientation of the insert.
- the resulting colonies were tracked by digestion with the appropriate restriction enzymes.
- the binding sequences of the inserts were sequenced by the dideoxynucleotide method [Sanger et al., Cited supra] using the oligonucleotide shown in SEC. ID. N .: 7 as initiator.
- BL21 (DE3) pLysS (Studier et al., Cited supra] competent cells were transformed with the plasmid pET-PRRSVORF7E previously prepared in order to express the PRRSV nucleocapsid protein in the form of a fusion protein with the product of gene 10 of phage T7.
- agar plates with chloramphenicol and ampicillin were used. 3.3 Growth, induction and analysis of transformed E. coli cells.
- the recombinant protein contains the rest of amino acids derived from the product of gene 10 of T7 (amino acids 1 to 259), a zone of union of 6 amino acids (amino acids 260-265) and the protein sequence of the Complete nucleocapsid of the European isolate of PRRSV (amino acids 266-393).
- the fusion protein obtained is insoluble although it can be easily solubilized with 4M guanidinium chloride.
- the purity of the fusion protein obtained after the solubilization step is greater than 80%.
- Recombinant fusion proteins were transferred to nitrocellulose membranes using the semi-dry transfer technique (Bio-Rad) for 20 minutes at 22 Volts. Then, the membranes were incubated for 1 hour in blocking solution (3% skim milk, 0.05% Tween® 20 in PBS). After blocking, the proteins were reacted with the supernatants of specific monoclonal antibodies against the nucleocapsid protein (identified as 1AC7, 1AG11, 1DA4, 1BD11, 1EB9, 1CH5 and 1DH10) [Second Symposium on Aujeszky and PRRS viruses, Copenhagen, Denmark (1995)] overnight at 4 ° C.
- 1DH10 defined another antigenic site and recognized a discontinuous epitope that requires the complete nucleocapsid.
- the reactivity of the monoclonal antibodies was characterized by an indirect ELISA assay under conditions where the protein was closer to its appropriate folding.
- ELISA 96-well microtiter plates (LabSystem) were coated overnight at 4 ° C with 100 ⁇ l of a 1: 100 dilution of the recombinant fusion protein containing the nucleocapsid protein of the European PRRSV isolate , expressed by E. coli and solubilized with 4 M guanidinium chloride in 0.05 M carbonate buffer, pH 9.6. The plates were then incubated with the undiluted supernatants of the monoclonal antibodies or with double serial dilutions of the animal's serum corresponding for 2 hours at 37 ° C.
- PRF-E monoclonal antibody Toledo 4/96 1CH5 ++ 1DH10 ++
- PRF-E recombinant fusion protein containing the nucleocapsid protein of the European PRRSV isolate.
- Example 4.1 Cloning of the ORF7
- the procedure described in Example 3.1 was repeated exactly, but using the product resulting from the PCR amplification of Example 2, corresponding to the complete sequence of the 0RF7 of the American isolate, thereby cloning it into the plasmid pMTL25 previously digested with Smal and treated with phosphatase obtained the plasmid called pPRRSC-0RF7.
- Plasmid DNA was sequenced according to the dideoxynucleotide method [Sanger et al., Cited supra], while the analysis of the amino acid sequence of the protein was performed with the PC / GENE program and PredictProtein [Rost et al., Cited supra].
- the amino acid sequence of the nucleocapsid protein of the American PRRSV isolate is shown in SEC. ID. N .: 2.
- Plasmid pET3x containing the complete sequence of the PRRSV nucleocapsid protein was called pET-PRRSVORFC and was used to transform competent E. coli XLl blue or DH5 cells. The resulting colonies were tracked by digestion with the appropriate restriction enzymes. To check the orientation, the sequences Binding inserts were sequenced by the dideoxynucleotide method [Sanger et al., cited supra] using the oligonucleotide shown in SEQ. ID. No. : 7 as initiator.
- BL21 (DE3) pLysS (Studier et al., Cited supra] competent cells were transformed with the plasmid pET-PRRSVORF7C previously prepared in order to express the PRRSV nucleocapsid protein in the form of a fusion protein with the product of gene 10 of phage T7.
- agar plates with chloramphenicol and ampicillin were used.
- the complete sequence of the recombinant fusion protein is shown in SEC. ID. No. : 9.
- the recombinant protein contains the rest of amino acids derived from the product of gene 10 of T7 (amino acids 1 to 259), a 4 amino acid binding zone (amino acids 260-263) and the complete nucleocapsid protein sequence of the American isolate of PRRSV (amino acids 264-386).
- the purification of said protein is carried out according to the methodology described by Mart ⁇ nez-Torrecuadrada et al. [quoted above].
- the fusion protein obtained is insoluble although it can be easily solubilized with 4M guanidinium chloride.
- the purity of the fusion protein obtained after the solubilization step is greater than 80% (determined by Coomassie blue staining).
- Example 3.5 The procedure described in Example 3.5 was followed but in this case using the recombinant fusion protein containing the nucleocapsid protein of the American isolate of PRRSV. The results obtained by ELISA are shown in Table 2. Table 2 Characterization of monoclonal antibodies that specifically recognize the PRRSV nucleocapsid protein
- PRF-E recombinant fusion protein containing the nucleocapsid protein of the European PRRSV isolate (SEQ ID NO: 8).
- PRF-C recombinant fusion protein containing the nucleocapsid protein of the American PRRSV isolate (SEQ. ID. NO .: 9).
- a competition ELISA assay can be performed where the use of the recombinant antigen is combined with the specificity of monoclonal antibodies In general, this test is more specific and more sensitive.
- 96-well microtiter plates (LabSystem) were coated overnight, at 4 ° C, with 100 ⁇ l (1 ⁇ g / well) of the recombinant fusion protein containing the protein of the nucleocapsid of the European isolate of PRRSV expressed in E. coli (Example 3) solubilized with 4 M guanidinium chloride in 0.05 M carbonate buffer, pH: 9.6. Then, 100 ⁇ l of the serum samples to be evaluated (15 samples, 6 positive and 9 negative), diluted 1/5 in PBS-Tween® 20 0.05%, were added and incubated for 30 minutes at 37 ° C . Without removing the sera, 50 ⁇ l of the peroxidase-labeled 1CH5 monoclonal antibody (1: 5000) was added in the same buffer described above and incubation was continued for an additional 30 minutes.
- the reaction was detected by adding ABTS as a substrate.
- the reaction was stopped by the addition of 1% SDS.
- the optical density of the samples was determined at 405 nm in an ELISA reader (Bio-Tek Instruments, United States). The results obtained are summarized in Table 4.
- CN is the absorbance value at 405 nm of the negative control and CP that of the positive control.
- a sample is considered positive if the absorbance value of said sample at 405 nm is less than the cut-off value. Otherwise, the sample is considered negative.
- pET-PRRSVORF7E The plasmid called pET-PRRSVORF7E, containing the complete nucleotide sequence encoding the nucleocapsid protein (ORF7) of the isolate of PRRSV Toledo 4/96 has been deposited on December 19, 1996 in the Spanish Type Culture Collection (CECT), Burjasot, Valencia (Spain), corresponding to the deposit number CECT 4836.
- NAME INMUNOLOG ⁇ A Y GENÉTICA APLICADA, S.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2276086A CA2276086C (en) | 1996-12-30 | 1997-12-24 | Recombinant fusion proteins of the porcine reproductive and respiratory syndrome virus (prrsv) and its use in diagnosis |
DE69734893T DE69734893T2 (de) | 1996-12-30 | 1997-12-24 | Rekombinante fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein (prrsv) und deren verwendung in der diagnose |
US09/331,924 US6468538B1 (en) | 1996-12-30 | 1997-12-24 | Recombinant proteins for the fusion of the porcine reproductive and respiratory syndrome virus and its use in diagnosis |
EP97947734A EP0952219B1 (en) | 1996-12-30 | 1997-12-24 | Recombinant fusion proteins of the porcine reproductive and respiratory syndrome virus (PRRSV) and its use in diagnosis |
AT97947734T ATE312925T1 (de) | 1996-12-30 | 1997-12-24 | Rekombinante fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein (prrsv) und deren verwendung in der diagnose |
AU53988/98A AU722732B2 (en) | 1996-12-30 | 1997-12-24 | Recombinant fusion proteins of the porcine reproductive and respiratory syndrome virus (PRRSV) and its use in diagnosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09602770A ES2122921B1 (es) | 1996-12-30 | 1996-12-30 | Proteinas recombinantes de fusion del virus reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico. |
ESP9602770 | 1996-12-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/331,924 A-371-Of-International US6468538B1 (en) | 1996-12-30 | 1997-12-24 | Recombinant proteins for the fusion of the porcine reproductive and respiratory syndrome virus and its use in diagnosis |
US10/147,951 Division US6592870B2 (en) | 1996-12-30 | 2002-05-17 | Method and kit using recombinant proteins in fusion of porcine reproductive and respiratory syndrome virus and for diagnosis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998029550A1 true WO1998029550A1 (es) | 1998-07-09 |
Family
ID=8297194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1997/000313 WO1998029550A1 (es) | 1996-12-30 | 1997-12-24 | Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico |
Country Status (9)
Country | Link |
---|---|
US (2) | US6468538B1 (es) |
EP (1) | EP0952219B1 (es) |
AT (1) | ATE312925T1 (es) |
AU (1) | AU722732B2 (es) |
CA (1) | CA2276086C (es) |
DE (1) | DE69734893T2 (es) |
DK (1) | DK0952219T3 (es) |
ES (2) | ES2122921B1 (es) |
WO (1) | WO1998029550A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73915C2 (uk) * | 1997-05-06 | 2005-10-17 | Стіхтінг Дінст Ландбаувкюндіг Ондерзук | Пептид, який індукує утворення нейтралізуючих антитіл (варіанти), антитіло, одержане за допомогою вказаного пептиду, імуногенна композиція для індукції нейтралізуючих антитіл, вакцина для профілактики зараження репродуктивно-респіраторним синдромом свиней (ррсс) та діагностичний набір для виявлення або ідентифікації антитіл, специфічних до ізоляту вррсс |
US6754889B1 (en) * | 2000-10-04 | 2004-06-22 | Compuware Corporation | Java automation, testing, and analysis |
CN101184997B (zh) | 2005-02-25 | 2017-06-13 | 艾德克斯实验室公司 | 用于检测抗猪繁殖呼吸综合征病毒抗体的肽 |
ES2311423B1 (es) | 2007-07-27 | 2010-01-07 | Inmunologia Y Genetica Aplicada, S.A. | Inmunoensayo de doble reconocimiento para la deteccion de anticuerpos. |
KR101258611B1 (ko) * | 2011-01-07 | 2013-04-26 | 유한회사 바이오노트 | 북미형 및 유럽형 prrsv 항원을 포함하는 분리된 단백질 및 그의 용도 |
CN104330572A (zh) * | 2014-10-27 | 2015-02-04 | 苏州市吴江区畜牧兽医站 | 一种用于间接ELISA检测猪PRRSV病毒IgG或IgA抗体的试剂盒 |
CN108653194B (zh) * | 2018-07-06 | 2020-09-29 | 中国科学院微生物研究所 | 一种以融合干扰素为活性成分的嚼糖剂型药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0717108A1 (en) * | 1994-05-13 | 1996-06-19 | Cyanamid Iberica, Sa | Recombinant prrs proteins, diagnostic kits and vaccines containing said recombinant proteins |
-
1996
- 1996-12-30 ES ES09602770A patent/ES2122921B1/es not_active Expired - Fee Related
-
1997
- 1997-12-24 WO PCT/ES1997/000313 patent/WO1998029550A1/es active IP Right Grant
- 1997-12-24 ES ES97947734T patent/ES2255114T3/es not_active Expired - Lifetime
- 1997-12-24 CA CA2276086A patent/CA2276086C/en not_active Expired - Fee Related
- 1997-12-24 DE DE69734893T patent/DE69734893T2/de not_active Expired - Lifetime
- 1997-12-24 DK DK97947734T patent/DK0952219T3/da active
- 1997-12-24 US US09/331,924 patent/US6468538B1/en not_active Expired - Lifetime
- 1997-12-24 AU AU53988/98A patent/AU722732B2/en not_active Ceased
- 1997-12-24 EP EP97947734A patent/EP0952219B1/en not_active Expired - Lifetime
- 1997-12-24 AT AT97947734T patent/ATE312925T1/de active
-
2002
- 2002-05-17 US US10/147,951 patent/US6592870B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0717108A1 (en) * | 1994-05-13 | 1996-06-19 | Cyanamid Iberica, Sa | Recombinant prrs proteins, diagnostic kits and vaccines containing said recombinant proteins |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
US6468538B1 (en) | 2002-10-22 |
AU722732B2 (en) | 2000-08-10 |
EP0952219B1 (en) | 2005-12-14 |
DE69734893D1 (de) | 2006-01-19 |
EP0952219A1 (en) | 1999-10-27 |
US20030108570A1 (en) | 2003-06-12 |
DE69734893T2 (de) | 2006-08-24 |
ES2122921B1 (es) | 1999-09-16 |
DK0952219T3 (da) | 2006-05-01 |
AU5398898A (en) | 1998-07-31 |
ATE312925T1 (de) | 2005-12-15 |
CA2276086C (en) | 2015-05-19 |
CA2276086A1 (en) | 1998-07-09 |
US6592870B2 (en) | 2003-07-15 |
ES2122921A1 (es) | 1998-12-16 |
ES2255114T3 (es) | 2006-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1265648A (en) | Leukemia-associated virus immunogen, vaccine and assay | |
KR870000702B1 (ko) | 합성 항원 펩티드의 제조방법 | |
Risco et al. | Membrane protein molecules of transmissible gastroenteritis coronavirus also expose the carboxy-terminal region on the external surface of the virion | |
JP3846808B2 (ja) | ペスチウイルス株のヌクレオチド配列、それらの配列によりコードされるポリペプチド、ならびにペスチウイルス感染の診断および予防のためのそれらの使用 | |
US6280974B1 (en) | Recombinant feline coronavirus S proteins | |
Chirnside et al. | Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus | |
CA2523875A1 (en) | Sars virus nucleotide and amino acid sequences and uses thereof | |
CN114874995B (zh) | 猪瘟病毒2型Erns蛋白的单克隆抗体杂交瘤细胞株及应用 | |
Jacobs et al. | Epitope analysis of glycoprotein I of pseudorabies virus | |
ES2255114T3 (es) | Proteinas recombinantes de fusion del virus del sindrome reproductivo y respiratorio porcio (prrsv) y su empleo en diagnostico. | |
Chirnside et al. | Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus | |
US20040063093A1 (en) | Recombinant feline coronavirus S proteins | |
ES2146574T5 (es) | Secuencias de nucleotidos y polipeptidos, en particular del virus del colera del cerdo. | |
KR102138287B1 (ko) | 돼지 생식기 및 호흡기 증후군 바이러스 진단용 유전형별 재조합 항원 단백질 및 이의 용도 | |
EP0811067A1 (en) | Equine arteritis virus peptides, antibodies and their use in a diagnostic test | |
Sinclair et al. | Detection of antibodies against equine herpesvirus types 1 and 4 by using recombinant protein derived from an immunodominant region of glycoprotein B | |
US6090390A (en) | Diagnostic test for equine arteritis virus mediated disease | |
KR102091279B1 (ko) | 돼지 생식기 및 호흡기 증후군 바이러스 진단용 재조합 항원 단백질 및 이의 용도 | |
KR100430935B1 (ko) | 대장균 발현 재조합 3abc 비구조단백질 및단클론항체를 이용한 구제역 진단방법 | |
WO2009053512A1 (es) | Proteínas n, m, he de torovirus porcino, procedimiento de obtención y sus aplicaciones en diagnóstico y tratamiento de torovirus porcino. | |
WO2004062567A2 (en) | Arterivirus marker vaccine | |
WO2001068683A2 (en) | Peptide fragments of the equine arteritis virus m protein and their use in diagnostic tests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2276086 Country of ref document: CA Ref country code: CA Ref document number: 2276086 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09331924 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997947734 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 53988/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1997947734 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 53988/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997947734 Country of ref document: EP |